Table 1.
Univariable and multivariable analyses of the clinicopathological characteristics and metabolic parameters at baseline for pathological complete response in 199 breast cancers
| n | Univariable | p value | Multivariable | p value | |
|---|---|---|---|---|---|
| [OR (95% CI)] | [OR (95% CI)] | ||||
| Menopausal status | |||||
| Premenopausal | 80 | 1.00 | |||
| Postmenopausal | 119 | 1.59 (0.85–2.96) | 0.1447 | ||
| T size (cm) | |||||
| ≤ 2.0 | 43 | 1.00 | 1.00 | ||
| > 2 | 156 | 0.40 (0.20–0.80) | 0.0093 | 0.40 (0.13–1.20) | 0.1024 |
| Lymph node metastasis | |||||
| Negative | 104 | 1.00 | |||
| Positive | 95 | 0.65 (0.36–1.20) | 0.1677 | ||
| Nuclear grade | |||||
| 1 | 74 | 1.00 | 1.00 | ||
| 2 + 3 | 115 | 5.76 (2.62–12.66) | < 0.0001 | 3.14 (1.09–9.04) | 0.0342 |
| Ki67 expression levelsa | |||||
| Low | 50 | 1.00 | 1.00 | ||
| High | 139 | 9.74 (2.89–32.89) | 0.0002 | 20.58 (1.55–237.07) | 0.0219 |
| Subtypesb | |||||
| TN | 48 | 1.00 | 1.00 | ||
| Luminal A | 31 | 0.04 (0.01–0.34) | 0.0029 | 2.23 (0.08–65.78) | 0.6418 |
| Luminal B | 49 | 0.18 (0.06–0.50) | 0.0010 | 0.20 (0.06–0.67) | 0.0114 |
| Luminal-HER2 | 36 | 0.57 (0.23–1.41) | 0.2198 | 1.18 (0.34–4.09) | 0.7908 |
| HER2 | 33 | 3.43 (1.32–8.91) | 0.0114 | 5.45 (1.53–19.41) | 0.0089 |
| Chemotherapy regimen | |||||
| Taxane | 48 | 1.00 | 1.00 | ||
| Anthracycline and taxane | 142 | 3.26 (1.42–7.47) | 0.0053 | 2.83 (0.92–8.77) | 0.0707 |
| SUVcmax | |||||
| Low | 60 | 1.00 | |||
| High | 139 | 2.10 (1.04–4.24) | 0.0396 | Not included | |
| SUVdpeak | |||||
| Low | 62 | 1.00 | |||
| High | 137 | 2.24 (1.11–4.51) | 0.0249 | Not included | |
| SUVemean | |||||
| Low | 47 | 1.00 | |||
| High | 152 | 2.84 (1.24–6.52) | 0.0135 | Not included | |
| MTVf | |||||
| Low | 71 | 1.00 | |||
| High | 128 | 0.33 (0.18–0.62) | 0.0005 | 0.30 (0.11–0.84) | 0.0212 |
| TLGg | |||||
| Low | 110 | 1.00 | |||
| High | 89 | 0.43 (0.23–0.81) | 0.0092 | Not included | |
OR odds ratio, CI confidence interval, TN triple-negative, ER estrogen-receptor, HER2 human epidermal growth factor receptor 2, SUVmax maximum standardized uptake value, SUVpeak peak standardized uptake value, SUVmean mean standardized uptake value, MTV metabolic tumor volume, TLG total lesion glycolysis
aLow < 20%, high ≥ 20%
bTN, ER-negative/HER2-negative; Luminal A, ER-positive/HER2-negative with Ki67 < 20%; Luminal B, ER-positive/HER2-negative with Ki67 ≥ 20%; Luminal-HER2, ER-positive/HER2-positive; HER2, ER-negative/HER2-positive
cLow < 3.664, high ≥ 3.664
dLow < 3.279, high ≥ 3.279
eLow < 1.782, high ≥ 1.782
fLow < 4.416, high ≥ 4.416
gLow < 20.138, high ≥ 20.138